Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Bristol-Myers Squibb Company stock (US0897961004): Is its oncology dominance strong enough to drive
Bristol-Myers Squibb (BMS) relies heavily on its oncology portfolio, featuring blockbuster drugs like Opdivo and Revlimid, to drive revenue. The company is strategically focused on expanding its immuno-oncology leadership, diversifying into precision medicine, and managing patent cliffs, particularly for Revlimid. Investors are watching its pipeline and strategic acquisitions to ensure sustained growth and reliable returns amidst increasing competition and regulatory scrutiny.